INTRODUCTION
The global public health burden associated with hepatitis C virus (HCV) infection is growing, [1] with an estimated >185 million HCV antibody-positive individuals in 2005, relating to a global prevalence of 2.8%. [2] At the national level, disease modelling exercises [3] [4] [5] [6] [7] ) suggest that HCV-related disease burden will continue to increase with current low rates of antiviral treatment. These models illustrate that the annual number of HCV patients initiated on treatment would need to be radically increased to counteract the projected rise in disease burden.
In Scotland, a country with approximately 39,000 people currently estimated to be chronically infected with HCV (0.8% of the general population), [8] the annual numbers of patients initiated on antiviral therapy has approximately doubled between 2007/2008 (n = 468) and 2010/2011 (n = 1049) as a result of the Scottish Government's HCV Action Plan [9] and significant investment. [8, 10] This Plan aimed to ensure those infected receive optimal treatment, care and support, through nationally agreed guidelines, standards and targets and accountable national and local multi-disciplinary networks responsible for the planning, development and delivery of services. A considerable emphasis was placed on co-ordination and monitoring to ensure progress was made. A HCV clinical database was thus established in almost all specialist centres delivering HCV treatment -a data-monitoring initiative unique to Scotland -and provided an opportunity to explore the impact of this scaling-up in the delivery of antiviral therapy, with respect to both the characteristics and sustained viral response (SVR) rates of treated patients. Data at the international level is non-existent in this respect, despite recent increases in the number of patients treated for HCV across parts of Europe, Asia, and the Middle East. [11] Moreover, it was unknown if scaling-up might have an associated reduction in SVR as a consequence of, for instance, specialist services being unable to cope with new demand and the administration of therapy to less-compliant individuals. This investigation will be highly relevant and provide vital evidence for other countries either planning or in the process of scaling-up HCV treatment.
METHODS

Data source
We extracted the clinical treatment data for all 17 specialist clinics delivering HCV treatment in Scotland, over the 10-year period from the start of 2001 to the end of 2010, from the Scottish Hepatitis C Clinical Database held at Health Protection Scotland. [12] The patient population was restricted to those initiated on combined pegylated interferon and ribavirin (pegI&R) antiviral therapy, because we wished to distinguish any changes in SVR from improvements in antiviral therapy available. A total of 3,999 patients were initiated on at least one pegI&R treatment course within the study period.
Design and variables
Thirteen specialist clinics providing outpatient HCV treatment were included in analysis: cirrhosis was based on one or more of the following criteria: (i) clinical examination; (ii) radiology (i.e., ultrasound, FibroScan, computed tomography, or magnetic resonance imaging procedure); (iii) liver biopsy. [12] All variables were treated as cross-sectional variables, meaning that SVR was converted to a proportion, and all covariates except age were converted to percentages within each clinic-year combination; mean age was calculated within each clinic-year.
Statistical analyses
Analysis (a) investigated temporal trends in patients characteristics over the study period.
Mixed-effects linear regression models were fitted separately for each covariate, with year as the single fixed effect (with 2001/2002 coded as 2001.5) and clinic specified as a random intercept, given the non-independence of observations within clinics. For analyses with a proportion as the response variable (i.e., all covariates except age), the logit link function was specified; for these models, β coefficients are interpreted as log odds ratios, so are instead reported as exp(β), the odds ratio. PWID was defined as the proportion of PWID risk among patients with known risk only (i.e. patients with the status not known were excluded). Analysis (b) describes temporal trends in SVR over the study period, by fitting a mixedeffects linear regression model with year as the single fixed effect and clinic as a random intercept. A comparable analysis was also conducted on the study population excluding patients with diagnosed cirrhosis.
In analysis (c), we fitted time-series cross-sectional (TSCS) regression models appropriate for our data; these models can specify grouping variables as fixed or random effects. We attempted to isolate any unique effects on SVR that were associated with changing patient characteristics due to broadening of the eligible treatment patient population (e.g., the percentage of PWID patients, the percentage of referrals from prison settings) over the study period, by adjusting for other covariates. A Hausman test was conducted to assess the appropriateness of specifying clinic as a random effect rather than a fixed effect, and the need to include year as an additional fixed effect was assessed using a Lagrange multiplier test. In this type of regression model, a single regression coefficient fitted for a given covariate (e.g., PWID) aggregates both between-clinic and within-clinic effects (i.e., time-invariant and timevarying components of the covariate effect). [13] Therefore, a test for equality of these parameters was conducted before final model specification, [13, 14] and if necessary, All regression models were fitted using the lme4 [15] and plm [16] packages for the R statistical computing environment (version 3.0.0). [17] RESULTS Figure 1 illustrates the growth of the treated population over the study period, showing both the cumulative numbers of patients initiated on pegI&R treatment and the cumulative number of SVR achieved, in 17 Scottish specialist clinics over the period 2001-2010. Table 1 summarises the characteristics of our study population according to calendar year period of initiation on antiviral therapy. There was an increase in the overall number of patients proportion of treated patients with diagnosed cirrhosis (OR = 0.84, p < 0.0001; i.e. there was a 16% decrease in the odds of a treated patient having diagnosed cirrhosis). Significant increasing temporal trends were found for the within-clinic proportion of treated patients with PWID risk (OR=1.08, p = 0.026) and prison referral (OR = 1.06, p = 0.002). In the last year of the study period, an across-clinic mean of 57%, 11%, 77% and 6.7% treated patients were HCV genotype 2 or 3, had diagnosed cirrhosis, were current/former PWID, or were referred from a prison setting, respectively.
The SVR temporal trend (analysis (b)) for individual clinics, and the trend of the mean over all clinics, is displayed in Fig. 3 . At the clinic level, there was a non-significant overall increasing trend in the proportion of treated patients achieving SVR over the study period (odds ratio [OR] per year = 1.03, p = 0.33; in other words, a 3% increase in the odds of achieving SVR per year), from an across-clinic mean of 44% in 2001/2002 to 56% in 2010.
Stratified analyses conducted according to genotype (i.e., separately for genotype 2/3 and for other genotypes) indicated similar SVR temporal trends ( Fig. 3) . A supplementary analysis (Appendix , Table A2 and Fig. A2 ) conducted on only those patients without diagnosed cirrhosis (n=3297) also did not indicate any trend in the proportion achieving SVR, from across-clinic mean of 51% in 2001/2 to 58% in 2010 (OR = 0.97, p = 0.38). Note that the lines indicating across-clinic means in these SVR plots do not show variability, and thus only serve to visually indicate temporal trends.
The covariates of interest are all plausibly associated with SVR, but apparent crude associations between a temporal trend in SVR and a trend in a particular covariate may be confounded by other, related variables. Therefore, we also estimated the associations between within-clinic proportions achieving SVR and within-clinic patient characteristics after adjusting for other covariates (analysis (c)). Male sex and weekly alcohol consumption were excluded from the adjusted model, as no crude association was observed with SVR. Based on the Hausman test result, clinic was specified as a random effect. The final fitted mixed-effects regression model is presented in Table 2 Adjusting for the other covariates, there was a significant 1.027-fold increase in the odds of SVR (95% CI: 1.016-1.037) with every percentage increase in HCV genotype 2/3 patients treated over time ( Table 2) . For a given clinic, there was a statistically significant 1.012-fold increased odds of SVR with every percentage increase in PWID treated over time.
In individual-level analyses (Appendix , Table A1) 
DISCUSSION
The current study represents the first evidence investigating temporal trends in response to to 1560 in 2009-2010 -and changes in patient characteristics over the same period -SVR rates were not compromised. Temporal trends in several patient characteristics known to be associated with SVR rates [12] were found; namely, within clinics there were increased odds of treated patients with PWID status and referred from prison settings, and decreased odds of treated patients with diagnosed cirrhosis, but there was no evidence that the proportion of patients achieving an SVR was affected. There was also no evidence that the greater proportion of diagnosed cirrhotic patients treated in the earlier part of the study period concealed a downward trend in SVR rates, as excluding these patients from analysis did not change the results.
Our main finding authenticates the assumption -of SVR rates being maintained, despite the broadening of the treated patient base -employed in numerous modelling studies (recently those reported in [18, 19] ) predicting the impact of scaling-up therapy.
For a given clinic, a higher proportion of SVR was associated with genotype 2/3 HCV compared with all other genotypes (adjusting for other covariates), which is consistent with previous studies. [12, [20] [21] [22] Both the unadjusted and adjusted TSCS analysis indicated a positive association between SVR and the proportion of patients who were current or former PWID, which was unexpected. This cannot be interpreted as a causal association (e.g., more PWID initiated on treatment gives rise to a greater SVR rate), because a single regression coefficient in the TSCS analysis aggregates time-invariant and time-varying components of the covariate effect. That is, a greater proportion of PWID may be treated within clinics that have better overall SVR rates than within clinics with lower rates. [14] Because the individual- comm.], which is only slightly higher than that observed here for patients treated during 2009-2010 (10%). Thus, our findings still suggest that greater effort is needed to identify and treat those with more advanced disease.
We restricted the dataset to treatment initiations on pegI&R; otherwise, we could not distinguish a possible rising trend in SVR rates from improvements in antiviral therapy during the same period. However, the proportion achieving a SVR was quite stable over the study period. Another limitation is the paucity of data in the earliest years of the study period. In 2001-2, there was an average of 14 patients per clinic initiated on antiviral therapy; therefore the clinic-specific covariate estimates in the early part of the study period will not be as stable as estimates for later years.
Our intention-to-treat analysis, while appropriate for the research questions, also means that SVR proportions are lower than if we had excluded patients without PCR test results following the end of treatment (n=134; 3.4%) or persons otherwise lost to follow-up from the denominator. This would slightly restrict the variability in SVR across clinics and over time,
weakening the strength of possible associations with the covariates of interest.
Finally, because active injecting status is not recorded in the Scottish Hepatitis C Clinical database, we were unable to determine whether the rising trend observed in the proportion of treatment patients who are PWID (i.e., those either currently or formerly injecting drugs) also applies to those who were actively injecting drugs. It may be that increasing numbers of relatively stable patients with a past history of injecting drug use and with mild disease were initiated on treatment, possibly as a consequence of the Scottish Government's HCV Action
Plan. [9] If younger PWID (i.e.,. <35 years of age) are taken as a proxy for active injectors, then a rising trend in this group is still apparent (data not shown). The role of antiviral therapy in reducing transmission among PWID has been previously highlighted in modelling studies, [24] and there is accumulating evidence that the scale-up of interventions among those who actively inject in Scotland -principally injecting equipment provision and opiate substitute therapy, but potentially also antiviral therapy -has lead to a reduction in the incidence of HCV infection. [25] [26] [27] Antiviral treatment uptake remains low internationally; with <5% of chronically infected patients treated per year across most of Europe, [28] Australia, [29] and USA. [30] There are however promising new interferon-free therapies forthcoming: so called direct-acting antivirals (DAA), which should allow much higher SVR rates to be achieved, even among those with cirrhosis. [31, 32] The availability of these new effective treatments will mean that countries will be looking at scaling-up therapy delivery at the national level. In Scotland, the scale-up in treatment uptake was achieved [10] Although published data on the impact of treatment scale-up on SVR rates in other countries are scarce, success (in terms of treatment uptake) is notable for France, who have had a National Plan for Hepatitis B and C in place since 1999. [33] France achieved a treatment rate of 16% in 2005, and a reported 10,000 patients were initiated on antiviral therapy in 2011. [34] Common to both National strategies in France and Scotland has been a robust evidence base and reliable epidemiological data to drive policy, with quantifiable goals providing important motivation for success. [35] In summary, the comprehensiveness of Scotland's clinical treatment database has provided a unique opportunity to investigate the impact on SVR rates of broadening treatment to those patient groups who are often ineligible for clinical trials (e.g., PWID, incarcerated individuals), but nevertheless account for the majority of the chronically infected population.
SVR rates did not appear to be compromised, despite the broadening of the eligible patient base associated with the implementation of the HCV Action Plan and other initiatives.
Monitoring the characteristics of treated patients will be vitally important over the coming years to ensure that the patients who receive treatment are those who are most in need. The present results are highly relevant to countries planning on scaling-up treatment, given the forthcoming availability of new interferon-free therapies. analysis (a) ). The cumulative number of non-SVRs is the difference between green and red series. where individual clinics are indicated with grey lines and the across-clinic mean is indicated with a weighted black line. Note: OR = odds ratio; 95% CI = approximate 95% confidence interval; PWID = people who inject drugs 24 Fig. A1 . SVR over the study period (2001/2 to 2010), stratified by genotype category and risk group. Genotype 2/3 is indicated with a solid line; other genotypes with a broken line.
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25 Table A2 . Odds-ratio transformed coefficients from fitted mixed-effects regression models applied to the study population without diagnosed cirrhosis (n=3297); the dependent variable is logit-transformed proportion SVR at the clinic level. 
